Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer

Clinical Lung Cancer

Volumn 17, Issue 6, 2016, Pages 535-542

  Pore, Milind ^a   Meijer, Coby ^a   de Bock, Geertruida H ^a   Boersma van Ek, Wytske ^a   Terstappen, Leon W M M ^b   Groen, Harry J M ^a   Timens, Wim ^a   Kruyt, Frank A E ^a   Hiltermann, T Jeroen N ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

c MET; CSCs; CTCs; EMT; SCLC

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR SOX2; TUMOR MARKER; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG BIOPSY; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PROTEIN EXPRESSION; SMALL CELL LUNG CANCER; TUMOR BIOPSY; ADENOCARCINOMA; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR EMBOLISM; TUMOR INVASION;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84977657615     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.05.015     Document Type: Article

References (36)

1. 1 Govindan, R., Page, N., Morgensztern, D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24 (2006), 4539–4544.
2. 2 Paumier, A., Le Pechoux, C., Radiotherapy in small-cell lung cancer: where should it go?. Lung Cancer 69 (2010), 133–140.
3. 3 Rodriguez, E., Lilenbaum, R.C., Small cell lung cancer: past, present, and future. Curr Oncol Rep 12 (2010), 327–334.
4. 4 Simon, G.R., Wagner, H., American College of Chest Physicians. Small cell lung cancer. Chest 123:1 suppl (2003), 259S–271S.
5. 5 Simon, G.R., Turrisi, A., American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:3 suppl (2007), 324S–339S.
6. 6 Krebs, M.G., Metcalf, R.L., Carter, L., Brady, G., Blackhall, F.H., Dive, C., Molecular analysis of circulating tumour cells—biology and biomarkers. Nat Rev Clin Oncol 11 (2014), 129–144.
7. 7 Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15 (2014), 178–196.
8. 8 Nguyen, L.V., Vanner, R., Dirks, P., Eaves, C.J., Cancer stem cells: an evolving concept. Nat Rev Cancer 12 (2012), 133–143.
9. 9 Reya, T., Morrison, S.J., Clarke, M.F., Weissman, I.L., Stem cells, cancer, and cancer stem cells. Nature 414 (2001), 105–111.
10. 10 Beck, B., Blanpain, C., Unravelling cancer stem cell potential. Nat Rev Cancer 13 (2013), 727–738.
11. 11 Sourisseau, T., Hassan, K.A., Wistuba, I., et al. Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?. J Thorac Oncol 9 (2014), 7–17.
12. 12 Wang, P., Gao, Q., Suo, Z., et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One, 8, 2013, e57020.
13. 13 Masui, S., Nakatake, Y., Toyooka, Y., et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9 (2007), 625–635.
14. 14 Sanada, Y., Yoshida, K., Ohara, M., Oeda, M., Konishi, K., Tsutani, Y., Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32 (2006), 164–170.
15. 15 Rudin, C.M., Durinck, S., Stawiski, E.W., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44 (2012), 1111–1116.
16. 16 Yuan, P., Kadara, H., Behrens, C., et al. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One, 5, 2010, e9112.
17. 17 Thiery, J.P., Acloque, H., Huang, R.Y., Nieto, M.A., Epithelial-mesenchymal transitions in development and disease. Cell 139 (2009), 871–890.
18. 18 Han, Y., Luo, Y., Zhao, J., Li, M., Jiang, Y., Overexpression of c-met increases the tumor invasion of human prostate LNCaP cancer cells and. Oncol Lett 8 (2014), 1618–1624.
19. 19 Sylvester, P., Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer. Clin Transl Med, 3, 2014, 30.
20. 20 Sato, M., Shames, D.S., Hasegawa, Y., Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology 17 (2012), 1048–1059.
21. 21 Ogunwobi, O.O., Liu, C., Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 28 (2011), 721–731.
22. 22 Canadas, I., Rojo, F., Taus, A., et al. Targeting epithelial-to-mesenchymal transition with met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res 20 (2014), 938–950.
23. 23 Engelman, J.A., Zejnullahu, K., Mitsudomi, T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
24. 24 Hiltermann, T.J.N., Pore, M.M., van den Berg, A., et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol 23 (2012), 2937–2942.
25. 25 Hou, J.M., Krebs, M., Ward, T., et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178 (2011), 989–996.
26. 26 Aceto, N., Bardia, A., Miyamoto, D.T., et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158 (2014), 1110–1122.
27. 27 Hou, J., Krebs, M., Ward, T., et al. Molecular characteristics of circulating tumour cells and circulating tumour microemboli in patients with lung cancer (abstract). J Thorac Oncol, 6, 2011, S670.
28. 28 Hou, J.M., Krebs, M.G., Lancashire, L., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30 (2012), 525–532.
29. 29 Yang, F., Gao, Y., Geng, J., et al. Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer. Int J Clin Exp Pathol 6 (2013), 2846–2854.
30. 30 Maddison, P., Thorpe, A., Silcocks, P., Robertson, J.F., Chapman, C.J., Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 70 (2010), 335–339.
31. 31 Coppola, D., Clarke, M., Landreneau, R., Weyant, R.J., Cooper, D., Yousem, S.A., Bcl-2, p53, CD44, and CD44v6 isoform expression in neuroendocrine tumors of the lung. Mod Pathol 9 (1996), 484–490.
32. 32 Sarvi, S., Mackinnon, A.C., Avlonitis, N., et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res 74 (2014), 1554–1565.
33. 33 Fischer, K.R., Durrans, A., Lee, S., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
34. 34 Chang, M.H., Lee, K., Lee, K.Y., Kim, Y.S., Kim, Y.K., Kang, J.H., Prognostic role of integrin beta1, E-cadherin, and rac1 expression in small cell lung cancer. APMIS 120 (2012), 28–38.
35. 35 Arriola, E., Canadas, I., Arumi-Uria, M., et al. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer 105 (2011), 814–823.
36. 36 Stovold, R., Meredith, S.L., Bryant, J.L., et al. Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. Br J Cancer 108 (2013), 1704–1711.